14.05.2018 – Protagen AG collaborates with UCSF to study better immuno-profiling of cancer patients receiving immunotherapy

Dortmund, Germany - 9th May, 2018 - Protagen AG has today announced the start of a collaboration with the University of California, San Francisco (UCSF) to utilize Protagen's SeroTag® technology to investigate the immuno-profiling of prostate cancer patients treated with checkpoint inhibitors and therapeutic vaccines.

 

Click here to read more.